| pubmed-article:15456081 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15456081 | lifeskim:mentions | umls-concept:C0035691 | lld:lifeskim |
| pubmed-article:15456081 | lifeskim:mentions | umls-concept:C0019196 | lld:lifeskim |
| pubmed-article:15456081 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:15456081 | lifeskim:mentions | umls-concept:C0021747 | lld:lifeskim |
| pubmed-article:15456081 | lifeskim:mentions | umls-concept:C0035525 | lld:lifeskim |
| pubmed-article:15456081 | lifeskim:mentions | umls-concept:C0524910 | lld:lifeskim |
| pubmed-article:15456081 | lifeskim:mentions | umls-concept:C0449297 | lld:lifeskim |
| pubmed-article:15456081 | lifeskim:mentions | umls-concept:C0332293 | lld:lifeskim |
| pubmed-article:15456081 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:15456081 | pubmed:dateCreated | 2004-9-30 | lld:pubmed |
| pubmed-article:15456081 | pubmed:abstractText | Hepatitis C virus (HCV)-RNA clearance seems to occur more slowly in HIV/HCV-coinfected patients than in HCV-monoinfected subjects treated with pegylated interferon alpha (peg-IFN) plus ribavirin (RBV). As a consequence, concern has arisen over the feasibility of following the treatment rules applied to HIV-negative patients with chronic hepatitis C. A total of 89 HIV/HCV-coinfected patients who had fully completed a course of peg-IFN plus RBV were analysed. Of these, 29 (32.6%) reached sustained virological response (SVR). Reductions >2 logs in plasma HCV-RNA occurred in 52 (58%) patients at week 12 of treatment (early virological response; EVR). None of patients who showed HCV-RNA drops <2 logs at week 12 reached SVR (negative predictive value: 100%). The positive predictive value of EVR was 56%. On the other hand, relapses occurred in 19 (39.6%) out of the 48 patients who had negative HCV-RNA at the end of treatment, and there were no differences noted when comparing patients with HCV genotypes 2/3 and 1/4. In summary, the quantitative assessment of plasma HCV-RNA at week 12 predicts the chance of SVR using peg-IFN plus RBV in HIV-positive patients with chronic hepatitis C, as it does in HIV-negative individuals. Thus, discontinuation of anti-HCV therapy, which is associated with frequent side effects, might be warranted in HIV/HCV-coinfected patients showing HCV-RNA reductions <2 logs at week 12 of treatment. On the other hand, relapses in virological responders were unexpectedly high in HIV/HCV-coinfected patients when treatment was provided following the rules applied to HIV-negative subjects. This is particularly relevant for HCV genotypes 2/3, which only rarely relapse in HIV-negative patients. Therefore, extending therapy (for 12 months in HCV genotypes 2/3 and perhaps for 18 months in HCV genotypes 1/4) might be warranted in HIV/HCV-coinfected patients showing EVR. | lld:pubmed |
| pubmed-article:15456081 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15456081 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15456081 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15456081 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15456081 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15456081 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15456081 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15456081 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15456081 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:15456081 | pubmed:issn | 1359-6535 | lld:pubmed |
| pubmed-article:15456081 | pubmed:author | pubmed-author:BarreiroPablo... | lld:pubmed |
| pubmed-article:15456081 | pubmed:author | pubmed-author:SorianoVincen... | lld:pubmed |
| pubmed-article:15456081 | pubmed:author | pubmed-author:González-Laho... | lld:pubmed |
| pubmed-article:15456081 | pubmed:author | pubmed-author:NúñezMarinaM | lld:pubmed |
| pubmed-article:15456081 | pubmed:author | pubmed-author:RomeroMiriamM | lld:pubmed |
| pubmed-article:15456081 | pubmed:author | pubmed-author:CaminoNuriaN | lld:pubmed |
| pubmed-article:15456081 | pubmed:author | pubmed-author:MaidaIvanaI | lld:pubmed |
| pubmed-article:15456081 | pubmed:author | pubmed-author:Martin-Carbon... | lld:pubmed |
| pubmed-article:15456081 | pubmed:author | pubmed-author:Garcia-Samani... | lld:pubmed |
| pubmed-article:15456081 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15456081 | pubmed:volume | 9 | lld:pubmed |
| pubmed-article:15456081 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15456081 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15456081 | pubmed:pagination | 505-9 | lld:pubmed |
| pubmed-article:15456081 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:15456081 | pubmed:meshHeading | pubmed-meshheading:15456081... | lld:pubmed |
| pubmed-article:15456081 | pubmed:meshHeading | pubmed-meshheading:15456081... | lld:pubmed |
| pubmed-article:15456081 | pubmed:meshHeading | pubmed-meshheading:15456081... | lld:pubmed |
| pubmed-article:15456081 | pubmed:meshHeading | pubmed-meshheading:15456081... | lld:pubmed |
| pubmed-article:15456081 | pubmed:meshHeading | pubmed-meshheading:15456081... | lld:pubmed |
| pubmed-article:15456081 | pubmed:meshHeading | pubmed-meshheading:15456081... | lld:pubmed |
| pubmed-article:15456081 | pubmed:meshHeading | pubmed-meshheading:15456081... | lld:pubmed |
| pubmed-article:15456081 | pubmed:meshHeading | pubmed-meshheading:15456081... | lld:pubmed |
| pubmed-article:15456081 | pubmed:meshHeading | pubmed-meshheading:15456081... | lld:pubmed |
| pubmed-article:15456081 | pubmed:meshHeading | pubmed-meshheading:15456081... | lld:pubmed |
| pubmed-article:15456081 | pubmed:meshHeading | pubmed-meshheading:15456081... | lld:pubmed |
| pubmed-article:15456081 | pubmed:meshHeading | pubmed-meshheading:15456081... | lld:pubmed |
| pubmed-article:15456081 | pubmed:meshHeading | pubmed-meshheading:15456081... | lld:pubmed |
| pubmed-article:15456081 | pubmed:meshHeading | pubmed-meshheading:15456081... | lld:pubmed |
| pubmed-article:15456081 | pubmed:meshHeading | pubmed-meshheading:15456081... | lld:pubmed |
| pubmed-article:15456081 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15456081 | pubmed:articleTitle | Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin. | lld:pubmed |
| pubmed-article:15456081 | pubmed:affiliation | Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain. vsoriano@dragonet.es | lld:pubmed |
| pubmed-article:15456081 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15456081 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:15456081 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15456081 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15456081 | lld:pubmed |
